natgillin/translations-raw huggingface dataset:
It is further disclosed that the percent amount of the water soluble species in the extraction solution by weight may be a value in a range selected from the group consisting of 0.25% to 13%, 0.5% to 8%, 0.8% to 5%, and 1.25% to 4%. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 2, gdje postotna količina u vodi topljivih vrsta po masi u ekstrakcijskoj otopini je vrijednost u opsegu odabranom iz grupe koja se sastoji od 0.25% do 13%, 0.5% do 8%, 0.8% do 5%, 1 1.25% do 4%.
The cell culture medium of any one of the preceding claims, wherein the mitogenic growth factor comprises EGF and/or FGF. 
navedeni agonist Wnt sadrži bilo kojeg od R-spondina 1-4 i/ili Wnt-3a; i/ili navedeni mitogeni faktor rasta je EGF.
The fuel element 10, which is about 20 mm long, optionally may be wrapped with cigarette paper to improve lighting of the charcoal fuel. 
LA Gorivi element 10, koji je dug oko 20 mm, opcijski može biti umotan sa cigaret papirom tako da se poboljšava paljenje ugljičnog goriva.
Device according to claim 1, characterized in that the pump (1) is an electrical or a mechanical one. 
Uređaj prema zahtjevu 1, naznačen time da pumpa (1) je električna ili mehanička pumpa.
a transferred magnetic pattern into a screen-printed patch of magenta-to-green optically variable magnetic ink (scale in centimeters). FIG. 3 a) an engraved pattern in a Plastoferrite flexible magnetic plate, magnetized perpendicular to the sheet extension; 
Slika 3 a) uzorak ugraviran u savitljivu magnetsku ploču izrađenu od Plastoferrita, koja je magnetizirana okomito na nastavak lista; b) magnetski uzorak prenesen na fleksografski otisak optički varijabilne magnetske tinte zelena-do-plave (razmjer u centimetrima).
Advantageously, the cholesterol lowering agent selected from statin derivatives to be used in the composition of the present invention is selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni derivat statina odabran iz skupine koju čine lovastatin, pravastatin i simvastatin.
The compound of any one of claims 1-6 wherein: 
Spoj bilo kojeg od patentnih zahtjeva 1-11 gdje je X odsutno.
A compound according to claim 22, wherein R16 is H, C1-C6alkyl or a 5 or 6 membered heterocycle, especially morpholine, piperidine or piperazine. 
Spoj u skladu sa zahtjevom 22, naznačen time, da R16 je H, C1-C6alkil ili 5- il 6-člani heterocikl, posebno morfolin, piperidin ili piperazin.
Enzyme activation can not only initiate tissue damage but induce increased inflammatory cell infiltration into the tissue, leading to more enzyme production and subsequent tissue damage. 
Aktiviranje enzima ne mora samo započeti oštećivanje tkiva, već 1 inducirati pojačanu infiltraciju upalnih stanica u tkivo, što dovodi do veće proizvodnje enzima koja uzrokuje oštećivanje tkiva.
R units have the formula: wherein X is chosen from: 
PATENTNI ZAHTJEVI Spoj formule: pri čemu je A prsten odabran od:
wherein cycloalkyl refers to astable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms having from three to fifteen carbon atoms; and alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms. 
kao izolirani stereoizomer ili njihova mješavina, ili kao njihova farmaceutski prihvatljiva sol, pri čemu se cikloalkil odnosi na stabilni nearomatski monociklički ili policiklički radikal ugljikovodika koji se sastoji isključivo od atoma ugljika i vodika koji ima od tri do petnaest atoma ugljika; te alkil se odnosi na ravni ili razgranati radikal lanca ugljikovodika koji se sastoji isključivo od atoma ugljika i vodika, nije nezasićen, te ima od jedan do dvanaest atoma ugljika.
is an amino acid residue selected from the group consisting of glutamic acid (E) and aspartic acid (D), 
Xs je aminokiselinski ostatak odabran iz skupine koju čine glutaminska kiselina (E) 1 asparaginska kiselina (D),
The AvPAL variant of claim 1, wherein the cysteine residues at positions 503 and 565 of AvPAL have been substituted by a serine residue (SEQ ID NO:11). 
AVvPAL varijanta u skladu s patentnim zahtjevom 1, naznačena time, da su cisteinski ostaci na položajima 503 i 565 AvPAL-a supstituirani serinskim ostatkom (SEQ ID NO:11).
The therapeutic hosiery item according to one or more of the preceding claims, characterized in that the count of the thread or threads for coating said elastomer yarn (1a) of said first rows of knitting (1) is comprised between 5.56 and 94.44 dtex. 
Terapeutska čarapa prema jednom ili više prethodnih zahtjeva, naznačena time, da se broj jedne niti ili više niti za prevlačenje spomenutog elastomernog konca (1a) spomenutih neparnih redova pletiva (1) nalazi između 5,56 i 94,44 deteksa.
for fiber-optic umbilical lines, set the communication frequencies for sending and receiving at applicable high band, receiving ship to shore communication, and low band, sending shore to ship communication, frequencies; and that by activating the transfer switch for switching from a shore type control module to a ship type control module, the control module or control modules are arranged to automatically revert to the settings corresponding to those of a ship type control module. 
za optičke umbilikalne kabele, postavljanje komunikacijskih frekvencija za slanje i primanje na prikladni visoki frekvencijski pojas, prijem komunikacije brod-obala, i niski frekvencijski pojas, slanje komunikacije obala-brod; i to aktivacijom sklopke za prebacivanje za prebacivanje iz obalnog tipa upravljačkog modula u brodski tip upravljačkog modula, upravljački modul ili upravljački moduli prilagođeni su da se automatski vraćaju na postavke koje odgovaraju onima na brodskom tipu upravljačkog modula.
having the sequence of SEQ ID NO: 3; or ii) having at least 99% identity to SEQ ID NO: 3 and is a hybrid capsid comprising regions of the AAV3B and AAV8 capsids. 
(i) ima sekvencu SEQ ID NO: 3; ili (1i) ima identitet najmanje 99 %-tno jednak sekvenci SEQ ID NO: 3 i jeste hibridni kapsid koji sadrži regije kapsida AAV3B i AAVS.
An intelligent schoolbag according to Claim 4, wherein, a notch is formed along the axis of the second mandrel at the end where the second mandril passes through the second through hole, a locking block is arranged on the second mandril at two ends of the notch, a first boss for locking together with the locking block is arranged in the second housing, a second boss for unlocking the locking block is arranged on the housing right below the first boss, the cross section length of the first boss is less than that of the second boss, the cross section of the first boss is trapezoid-shaped, and the locking block is opposite to a bevel edge of the first boss; the second boss is provided with an arc surface, the locking block and the arc of the second boss, the press plate is arranged on the bottom inside the storage spaces, and the storage spaces are formed on any side wall inside the schoolbag body, or on the bottom inside the schoolbag body. 
Inteligentna školska torba prema zahtjevu 3, naznačena time što, je urez oblikovan uzduž osi drugog vretena na kraju gdje drugo vreteno prolazi kroz drugi prolazni otvor, zaustavni blok (186) je smješten na drugo vreteno na dva kraja ureza, prva izbočina (188) za zaključavanje zajedno s blokom za zaključavanje je smještena u drugo kućište, druga izbočina (189) za otključavanje bloka za zaključavanje je smještena na kućištu odmah ispod prve izbočine, duljina presjeka prve izbočine je manja od druge izbočine, presjek prve izbočine je trapeznog oblika, a blok za blokiranje je nasuprot kosog ruba prvog izbočenja; drugo izbočenje je predviđeno s površinom luka, blok za blokiranje je nasuprot površini luka drugog izbočenja, pritisna ploča je smještena na dnu unutar prostora za pohranu, a prostori za pohranu su oblikovani na bilo kojoj bočnoj strani unutar tijela školske torbe, ili na dnu unutar tijela školske torbe.
prepared for administration to the subject prior to the subject experiencing muscle damage or disease; or 
Laminin-1 za primjenu prema zahtjevu 1, naznačenu time da je taj laminin-1 pripremljen za davanje dotičnoj osobi prije nego što pacijent pretrpi oštećenje ili oboljenje mišića.
The dispersion of MPL consists of the following steps: 
Datum podnošenja europske prijave patenta:
According to one embodiment the feed water is desalinated seawater, brackish water or brine, treated wastewater or natural water such as ground water, surface water or rainfall. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je ulazna voda desalinirana morska voda, boćata voda ili rasol, obrađena otpadna voda ili prirodna voda poput podzemne vode, površinske vode ili kišnice.
The pharmaceutical composition of claim 3, wherein the composition is formulated as a sterile, injectable form. 
Farmaceutski sastav 17 zahtjeva 3, naznačeno time da je sastav formuliran u sterilnom obliku, podobnom za ubrizgavanje.
in which R and R′ are as defined above; nitration of a compound of formula (VIII) to give a compound of formula (IX): 
(VIII) u kojem su R 1 R' definirani gore, b) nitriranje spoja formule (VIII) pri čemu nastaje spoj formule (IX): že m
A mouse embryonic stem cell whose genome comprises a replacement of a genomic fragment comprising exons 2-7 of a mouse CD47 gene at an endogenous mouse CD47 locus with a human genomic fragment comprising exons 2-7 of a human CD47 gene to form a humanized CD47 gene, 
umetanju genomskog fragmenta u lokus endogenog glodavčkog CD47 u glodavačkoj embrionskoj matičnoj stanici, gdje navedeni genomski fragment sadrži egzone 2-7 iz ljudskog gena CD47, čime se dobije humanizirani gen CD47 na lokusu endogenog glodavčkog CD47;
An aqueous pharmaceutical formulation comprising insulin glargine in a concentration of 200-650 U/mL of insulin glargine being equimolar to 200-650 IU human insulin, for use in providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
the hydrogel is cross-linked; and/or 
(b) je hidrogel umrežen; i/ili
Moreover, this hyperphosphorylation as well as the neurotoxic effects of B-amyloid are blocked by lithium chloride and by a GSK3B antisense mRNA. 
Osim toga, ovu hiperfosforilaciju, kao i neurotoksične učinke B-amiloida sprječava litijev klorid, ako 1 antisense mRNA za GSK3PB.
-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide: or a pharmaceutically acceptable salt thereof, and wherein said granule further comprises a surfactant, and wherein said pharmaceutical composition comprises a lubricant, and the concentration of said lubricant does not exceed 1% by weight of the pharmaceutical composition. 
[image] ili njegova farmaceutski prikladna sol, i gdje te granule dalje sadrže surfaktant, i gdje taj farmaceutski pripravak sadrži lubrikant, i koncentracija tog lubrikanta ne prelazi 1% težine farmaceutskog pripravka.
The absorbent product for personal care of claim 6, wherein the weight ratio of carboxymethylcellulose to hydroxyethylcellulose is from about 1:5 to 5:1 and citric acid is present in the amount of from 1% to 5% by weight relative to the combined weight of carboxymethylcellulose and hydroxyethylcellulose. 
Polimerni hidrogel u skladu s patentnim zahtjevom 9, naznačen time da ima udio bubrenja u destiliranoj vodi od 50 do 100. Polimerni hidrogel u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time da je težinski omjer limunske kiseline naspram karboksimetilceluloze u vodenoj otopini od 1% do 5%.
Here, inhalative application does not exclude these side-effects although they are generally less severe than with peroral or parenteral application. 
Ovdje, inhalativna primjena ne isključuje ove nuspojave, premda su općenito manje žestoke nego kod peroralne ili parenteralne primjene.
A method according to claim 13, wherein the water and water soluble organics are transformed into electricity in a direct methanol fuel cell. 
Metoda u skladu s patentnim zahtjevom 13, pri čemu su voda i u vodi topive organske tvari prevedene u elektricitet u izravnoj metanolskoj stanici goriva.
The method of claim 1 wherein the daily dose of R,R-glycopyrrolate is between 5 and 500 ug. The method of claim 1 wherein the daily dose of formoterol is between 200 and 5,000 ug. 
Uporaba prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da je dnevna doza R,R-glikopirolata od 5 do 500 ug, prvenstveno od 15 do 300 ug.
A pharmaceutical composition according to any one of claims 1 to 36, for use in a method of treatment of liver fibrosis, atherosclerosis, restenosis, Alzheimer's, Parkinson's, Huntington's chorea, amyotropic lateral sclerosis, spino-cerebellar degeneration, osteoarthritis, rheumatoid arthritis, diabetic retinopathy, anaemia, sickle cell anaemia, thalassaeimia, malaria, trypanosomiasis, helminthiasis, multiple sclerosis, autoimmune diabetes, lupus, atopic dermatitis, asthma, allergic rhinitis, or inflammatory bowel disease. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 36, naznačen time, da je za uporabu u postupku liječenja jetrene fibroze, ateroskleroze, restenoze, Alzheimer-ove bolesti, Parkinson-ove bolesti, Huntington-ove horeje, amiotropične lateralne skleroze, spino-cerebralne degeneracije, osteoartritisa, reumatoidnog artritisa, dijabetičke HR P20120341 T1 retinopatije, anemije, anemije srpastih stanica, talasemije, malarije, tripanosomijaze, helmintijaze, multiple skleroze, autoimunog dijabetesa, lupusa, atopičnog dermatitisa, astme, alergijskog rinitisa ili upalne bolesti crijeva.
dispersing the poly alpha-1,3-glucan fibrids of claim 1, optionally, with wood pulp in an aqueous medium to form a slurry; and 
dispergiranje fibrida poli alfa-1,3-glukana u skladu s patentnim zahtjevom 1, opcionalno, s drvnom celulozom u vodenom mediju kako bi se dobila gusta otopina; i
The injector of claim 1, wherein the wall of the container comprises a rigid wall or wherein the wall of the container comprises a flexible wall. 
Ubrizgač prema zahtjevu 1, naznačen time, što se stjenka (460, 604, 652, 722) spremnika (452, 602, 650, 720) sastoji od čvrste stjenke i fleksibilne stjenke.
a zone of horizontal parking or pre-assembly for at least one cage, which is located downstream of the second horizontal trolley; 
4)_zonu (41) za horizontalno parking ili prethodno sklapanje barem jednog kaveza (4), koja je smještena nizvodno kolica (6);
is selected from the group consisting of unsubstituted imidazolyl and substituted imidazolyl; 
do X4 su neovisno odabrani iz skupine koju čine C i N;
The basin according to one or more of the preceding claims, characterized in that said second waterproofing layer (19) for the inner face (17) of the hollow structure (16) is constituted by one or more sheets of EPDM or the like. 
Osnova sukladno jednom ili više prethodnih zahtjeva, naznačena time što je navedeni drugi vodootporni sloj (19) unutarnjeg dijela (17) šuplje strukture (16) načinjen od jednog ili više listova EPDM ili sličnih.
and Mycobacterium spp., wherein the Mycobacterium spp is optionally Mycobacterium tuberculosis; 
i Mycobacterium spp., pri čemu je Mycobacterium spp proizvoljno Mycobacterium tuberculosis;
A method of hydrogenating a carbon-carbon double bond conjugated with a carbonyl carbon in an 1,2-unsaturated carbonylic compound in gas phase, comprising the step of: 
Metoda za hidrogeniranje ugljik-ugljik dvostruke veze konjugirane s karbonil ugljikom u 1,2 nezasićenoj karbonilnoj tvari u plinskoj fazi, obuhvaća sljedeće korake:
The compound for use according to claim 7 wherein the disease is selected from non-malignant hyperproliferative disorders and malignant hyperproliferative disorders, specifically of hepatocellular carcinoma, colon adenoma and polyposis, colon adenocarcinoma, breast cancer, pancreas adenocarcinoma, Barrett's esophagus or other forms of neoplastic diseases of the gastrointestinal tract and the liver. 
Spoj za uporabu prema patentnom zahtjevu 10 naznačen time što je bolest izabrana od nemalignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, posebnoo hepatostaničnog karcinoma, adenoma debelog crijeva i polipoza, adenokarcinoma debelog crijeva, kancera dojke, adenokarcinoma pankreasa, Barett-ovog jednjaka ili drugih oblika neoplastičnih bolesti gastrointestinalnog trakta 1 jetre.
the index "n" corresponds to the valence of the element M'; 
indeks „n“ odgovara valenciji elementa M';
The present invention further relates to the use of pentadecapeptide salts of the present invention for the preparation of formulations for use as food supplement. DETAILED DESCRIPTION OF THE INVENTION 
Uporaba soli pentadekapeptida prema zahtjevima 1 i 2, naznačena time, da je za proizvodnju pripravaka koji se koriste kao živežne namirnice odnosno kao dodaci prehrani.
inulin, are available for fermentation during the transit in the colon up to the end of the colon. 
inulin, na raspolaganju su za fermentaciju tijekom prolaska kroz cijelo debelo crijevo, sve do njegova kraja.
A process as claimed in any one of claims 1 to 7, wherein, the amount of initialiser added in step (i) is calculated to deliver at least 0.035% of the Group IIa metal by weight of the liquid iron. 
Postupak prema bilo kojem od zahtjeva 1 do 3, gdje se količina inicijalizatora koji se dodaje u koraku (i) računa tako da se dobije najmanje 0.035% barija težinski prema tekućem željezu.
The method according to claim 1, wherein the weighted average is calculated using an equation EPMATHMARKEREP wherein wi indicates incremental weightage, MRi indicates RSRP values received for the plurality of neighbor cells, k indicates the periodic intervals of time of receiving the RSRP values and RSRPn is the weighted average of the RSRP values. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se ponderirani prosjek izračunava jednadžbom RSREP,, = čem, gdje w; označuje ponderiranje inkrementa, MR; označuje RSRP vrijednosti primljene za više i=0 Vi susjednih ćelija, k označuje periodne intervale vremena primanja RSRP vrijednosti, a RSRP,, je ponderirani prosjek
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte produced according to claim 9, in solution or in lyophilized form; 
(a) posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 8, u otopini ili u liofiliziranom obliku;
at least 85% of the cells in the population express detectable levels of CD181 (CXCR1), 
(vii) najmanje 85 % stanica u populaciji na svojoj površini izražava uočljive razine CD181 (CXCRI),
The composition of claim 1 wherein the acidic variants further comprise glycated variant, deamidated variant, and/or sialylated variant. The composition of claim 1 or claim 2 wherein the amount of the acidic variants is less than 25%. 
Sastav prema zahtjevu 1, naznačen time, da kiselinske varijante nadalje obuhvaćaju glikoziranu varijantu, Sastav prema zahtjevu 1 ili zahtjevu 2, naznačen time, da količina kiselinskih varijanti iznosi manje od 25%.
Fig. 11 is a cross-sectional view of a steel section profile used with the floor element of Fig. 10. 
SLI1 je pogled poprečnog presjeka profila čeličnog elementa sa slike 10.
It is caused by a disorder of fructose absorption resulting from the impairment of transport processes in the mucosa of the small intestine. Those affected suffer from unclear abdominal symptoms and, as a result of the bacterial breakdown of the carbohydrates passing into the colon, the production of intestinal gases is increased. The symptoms include, e.g. a feeling of bloating, flatulence, colic-like stomachache, watery diarrhea, and bowel sounds. 
Glukoza izomeraze za uporabu u skladu sa zahtjevom 4, naznačena time, što crijevna intolerancija fruktoze je uzrokovana poremećajem absorpcije fruktoze. Glukoza izomeraze za uporabu u skladu sa zahtjevom 4 ili 5, naznačena time, što liječenje obuhvaća smanjenje ili sprečavanje pojave simptoma intolerancije fruktoze odabranih iz osjećaja nadutosti, nadimanja, kolika kao bol u želudcu, vodenastog proljeva i crijevnih zvukova.
each R7 is independently H or CH3; and 
je, neovisno za svaku jedinicu, H ili CH3, i
Inhibiting effect on acid secretion in vitro in isolated rabbit gastric glands was measured as described by Berglindh et al. 
In vitro inhibirajući učinak na lučenje kiseline iz izoliranih zečjih želučanih žlijezda bilo je mjereno prema uputama Berglindh 1 sur.
The proportion of sheet material which is subjected to significant plastic strain, that is to say plastically strained to a value of 0.05 or more, is preferably at least 65% and more preferably over 80%, for example 90% to 100%. 
Lim (10) prema bilo kojem prethodnom zahtjevu, naznačena time da udio materijala za lim koji je podvrgnut plastičnoj deformaciji od 0.05 ili više je najmanje 65%.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 194, 174, 178, and 186 in which 1 or 2 amino acids are substituted, wherein said peptide induces a cytotoxic T cell specific to a cell expressing KIF20A. 
Peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, gdje navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34, te 358, u kojem su 1 ili 2 aminokiseline zamijenjene, izbačene ili dodane, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
about 50 mM arginine. The pharmaceutical formulation of claim 11, wherein the formulation is contained in a staked needle prefilled syringe. 
Farmaceutski pripravak prema patentnom zahtjevu 11, naznačen time, što se pripravak nalazi u napunjenoj štrcaljki s integriranom iglom.
In one aspect of the present invention, the GPR119 agonist is a compound of Formula (VI). 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist je selektivni GPRI19 agonist.
Preferably, the piercer 11 in this embodiment is positioned asymmetrically with relation to a central axis through the base unit 3 and base part 3 as can be appreciated from FIG. 8 c . 
U toj izvedbi bušilo 11 je smješteno ponajprije asimetrično u odnosu na središnju os, koja ide kroz osnovnu jedinicu 3 i osnovni dio 5, kao što se može vidjeti na slici 8c.
The process according to any one of claims 1 to 7, wherein the calcium carbonate is first contacted with the at least one acid having a pKa of less than or equal to 2.5 and during its addition, the calcium carbonate is also contacted with the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time da se kalcijev karbonat prvo dovodi u kontakt sa najmanje jednom kiselinom koja ima pK, od manje od ili jednako 2.5 1 tijekom njenog dodavanja, kalcijev karbonat se također dovodi u kontakt sa barem jednom u vodi topivom ne-polimernom organskom i/ili anorganskom slabom kiselinom i/ili vodikovom soli navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline.
The invention relates to a compound of formula (Ig-2): wherein R15 is cyclopropyl; 
Spoj formule (Ig-2): naznačen time što R je ciklopropil;